{
    "organizations": [],
    "uuid": "d8a9f781cd91e1967e3510b1b5db14a0973ac99d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-agenus-announces-combination-clini/brief-agenus-announces-combination-clinical-trials-of-anti-ctla4-anti-pd1-idUSASB0C1Q3",
    "ord_in_thread": 0,
    "title": "BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 3:40 PM / in 7 minutes BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1 Reuters Staff \nJan 22 (Reuters) - Agenus Inc: \n* AGENUS ANNOUNCES COMBINATION CLINICAL TRIALS OF ITS ANTI-CTLA4 (AGEN1884) & ANTI-PD1 (AGEN2034) \n* AGENUS INC - ANNOUNCED LAUNCH OF COMBINATION TRIAL WITH ITS PROPRIETARY ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T17:39:00.000+02:00",
    "crawled": "2018-01-22T17:55:30.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "announces",
        "combination",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "agenus",
        "inc",
        "agenus",
        "announces",
        "combination",
        "clinical",
        "trial",
        "agen1884",
        "agen2034",
        "agenus",
        "inc",
        "announced",
        "launch",
        "combination",
        "trial",
        "proprietary",
        "antibody",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}